For more information, visit: www.miltenyibiotec.com/lp/sta... Early implementation of effective analytical assay translation strategies paves the way for cell and gene therapy (CGT) advancement to market. View this roundtable discussion to hear expert thoughts on effective communication, risk mitigation, and regulatory considerations regarding assay translation from analytical development to quality control.
At Miltenyi Biotec, we designed a robust flow cytometry-based CGT analytics workflow. Facilitating compliance and scalability, it supports your CGT development from assay development through to commercialization. Experience seamless integration of consistent reagents, automated instrumentation, and audit-ready software. In synergy with tailored services, this workflow is designed to accelerate your journey toward commercial success.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,700 employees in 23 countries - all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.